52 completed, 6 unknown, 1 active not recruiting, 1 not yet recruiting. 27 Phase 3, 13 Phase 4, 12 Phase 2, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 26, Unknown 1 |
| Phase 4 | 13 | Completed 10, Unknown 2, Active not recruiting 1 |
| Phase 2 | 12 | Completed 10, Unknown 2 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Japanese Encephalitis: new trials by email Literature Review of Japanese Encephalitis trials Research Report on Japanese Encephalitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 | |
| Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus Japanese Encephalitis | Not yet recruiting | ANRS, Emerging Infectious Diseases | 4000 | 2025-10-15 | 2025-09-11 | |
| Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas Liaoning Chengda Inactivated Japanese Encephalitis Vaccine - Japanese Encephalitis | Phase 4 | Active not recruiting | Liaoning Chengda Biotechnology CO., LTD | 250 | 2024-11-14 | 2024-12-13 |
| Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine - Japanese Encephalitis, Measles | Phase 4 | Completed | Liaoning Chengda Biotechnology CO., LTD | 408 | 2024-03-02 | 2025-08-28 |
| Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization Japanese Encephalitis | Completed | Liaoning Chengda Biotechnology CO., LTD | 15357 | 2024-01-01 | 2025-08-28 | |
| An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Stamaril, Imojev, Ixiaro - Infectious Disease, Yellow Fever | Phase 2 | Unknown | Singapore General Hospital | 70 | 2022-09-28 | 2023-04-12 |
| Flavivirus Cross-priming Potential of IMOJEV IMOJEV - Japanese Encephalitis | Not applicable | Completed | University of Liverpool | 19 | 2021-04-16 | 2025-01-31 |
| Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province Japanese Encephalitis Vaccine (Vero Cell), Inactivated;, No prospective interventions - Japanese Encephalitis, Vaccine Preventable Disease | Phase 4 | Unknown | Zhejiang Provincial Center for Disease Control and Prevention | 712 | 2021-03-01 | 2022-11-15 |
| Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam JEVAX, JECEVAX - Japanese Encephalitis | Phase 3 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 655 | 2017-09-30 | 2018-09-17 |
| Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age JEVAX, JECEVAX - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 220 | 2017-06-02 | 2018-09-17 |
| Postmarketing Surveillance Study for IMOJEV® in Republic of Korea Japanese Encephalitis | Completed | Sanofi Pasteur, a Sanofi Company | 50 | 2016-07-21 | 2022-04-25 | |
| Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Measles-Rubella combined vaccine(MR), Japanese Encephalitis alive vaccine(JE) - Measles, Rubella | Phase 4 | Completed | Centers for Disease Control and Prevention, China | 1043 | 2015-08-01 | 2016-08-01 |
| Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj Japanese encephalitis vaccine - Japanese Encephalitis | Phase 4 | Completed | Boryung Pharmaceutical Co., Ltd | 94 | 2015-08-01 | 2017-02-06 |
| Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) - Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 250 | 2015-06-01 | 2022-03-28 |
| Safety and Immunogenicity of JECEVAX in Young Children JEVAX, JECEVAX-1, JECEVAX-0.8 - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 200 | 2015-04-01 | 2016-06-28 |
| Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine a live attenuated chimeric JE vaccine - Japanese Encephalitis | Not applicable | Completed | Chulalongkorn University | 50 | 2013-12-01 | 2016-01-20 |
| Post-licensure Safety Study of IMOJEV® in Thailand IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine - Japanese Encephalitis | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 10000 | 2013-11-01 | 2016-05-04 |
| Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Japanese encephalitis chimeric vaccine (JECV) - Japanese Encephalitis | Phase 4 | Unknown | Khon Kaen University | 88 | 2013-10-01 | 2013-10-08 |
| Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea IMOJEV - Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 119 | 2013-07-11 | 2022-03-28 |
| Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine, Live Attenuated Varicella Vaccine, live attenuated JE vaccine - Japanese Encephalitis, Chickenpox | Phase 4 | Completed | Changchun Keygen Biological Products Co., Ltd. | 497 | 2013-03-01 | 2014-02-24 |
Showing 20 of 62. Sign in to see all of them.
Encephalitis, Japanese (62) · Encephalitis (4) · Measles (4) · Rubella (4) · Yellow Fever (4) · Chickenpox (3) · Hepatitis A (3) · Mumps (3) · Rabies (3) · Communicable Diseases (2) · Dengue (2) · Malaria (2) · Vaccine-Preventable Diseases (2) · Adenoviridae Infections (1) · Arenaviridae Infections (1)
Arbovirus Infections (62) · Brain Diseases (62) · Central Nervous System Diseases (62) · Central Nervous System Infections (62) · Central Nervous System Viral Diseases (62) · Encephalitis, Arbovirus (62) · Encephalitis, Viral (62) · Flaviviridae Infections (62) · Flavivirus Infections (62) · Infections (62) · Infectious Encephalitis (62) · Mosquito-Borne Diseases (62) · Nervous System Diseases (62) · Neuroinflammatory Diseases (62) · RNA Virus Infections (62)
Japanese Encephalitis Vaccines (8) · Hepatitis A Vaccines (3) · Blood Specimen Collection (2) · SA-14-14-2 vaccine (2) · Chickenpox Vaccine (1) · ChimeriVax (1) · Immunization, Secondary (1) · Immunoglobulins, Intravenous (1) · Measles-Mumps-Rubella Vaccine (1) · MenACWY-CRM vaccine (1) · Rabies Vaccines (1) · Ribavirin (1) · Saline Solution (1) · Vi polysaccharide vaccine, typhoid (1) · Yellow Fever Vaccine (1)
Valneva Austria GmbH (15) · Sanofi Pasteur, a Sanofi Company (11) · Sanofi (7) · Liaoning Chengda Biotechnology CO., LTD (3) · National Institute of Hygiene and Epidemiology, Vietnam (3) · PATH (3) · Boryung Pharmaceutical Co., Ltd (2) · Novartis (2) · University of Liverpool (2) · ANRS, Emerging Infectious Diseases (1) · Centers for Disease Control and Prevention, China (1) · Changchun Keygen Biological Products Co., Ltd. (1) · Chulalongkorn University (1) · Helsinki University Central Hospital (1) · Indian Council of Medical Research (1)
Germany (7) · Thailand (7) · Australia (6) · China (6) · Austria (5) · South Korea (5) · United States (5) · Philippines (4) · Vietnam (4) · India (3) · Sri Lanka (2) · United Kingdom (2) · Bangladesh (1) · Cambodia (1) · Czechia (1)
Astrid Kaltenboeck, Ph.D. (3) · Thiem D Vu, MD., PhD. (3) · Huanyu Wang (2) · Nihal Abeysinghe, MD, MSc (2) · Susanne Eder (2) · Susanne Eder, Mag. (2) · Vera Kadlecek, Mag. (2) · Ajit Rayamajhi, MBBS, MD (1) · Anand Dubey, M.D (1) · Andrea Ayad, Dr. (1) · Anu Kantele, MD PhD (1) · Atul Shanker, Dr. (1) · Bakul B. Javadekar, M.D. (1) · ChenChang Shih (1)
PMID 20934459, PMID 19143532, PMID 20856164, PMID 20864814, PMID 21150279, PMID 21288804, PMID 22696017, PMID 22777096, PMID 23967083, PMID 24656175, PMID 24717964, PMID 24873986, PMID 25308927, PMID 25483480, PMID 25567119, PMID 25886645, PMID 26005163, PMID 26994987, PMID 27628323, PMID 27686833, PMID 27815383, PMID 27903416, PMID 28135273, PMID 29081368, PMID 29325161, PMID 29429815, PMID 30833160, PMID 30962094, PMID 32156630, PMID 32474892, PMID 36969244, PMID 39794472, PMID 41980877